The recommended dosage of Lumizyme is 20 mg/kg body weight administered every 2 weeks.
Administered by Intravenous Infusion
Lumizyme should be reconstituted, diluted and administered by a healthcare professional. Before administering to patients, Lumizyme must be:
- Reconstituted with sterile water for injection
- Diluted with 0.9% sodium chloride for injection
- Filtered through a 0.2µm low protein-binding, in-line filter
Indications and Usage
Lumizyme® (alglucosidase alfa) is a hydrolytic lysosomal glycogen-specific enzyme indicated for patients with Pompe disease (acid α-glucosidase (GAA) deficiency).
Effective August 1, 2014 the Lumizyme ACE Program® has been discontinued.
Patients, Healthcare Providers, and Facilities are no longer required to participate in the Lumizyme ACE (Alglucosidase Alfa Control and Education) Program® prior to prescribing or receiving Lumizyme.
Click here to read a letter sent to Healthcare Providers regarding this change.
NOTE: This website and all information on it is intended for U.S. audiences only.
LUMIZYME®(alglucosidase alfa) is a hydrolytic lysosomal glycogen-specific enzyme indicated for patients with Pompe disease (acid α-glucosidase (GAA) deficiency).
IMPORTANT SAFETY INFORMATION
WARNING: RISK OF ANAPHYLAXIS, HYPERSENSITIVITY AND IMMUNE-MEDIATED REACTIONS, and RISK OF CARDIORESPIRATORY FAILURE
Life-threatening anaphylactic reactions and severe hypersensitivity reactions, presenting as respiratory distress, hypoxia, apnea, dyspnea, bradycardia, tachycardia, bronchospasm, throat tightness, hypotension, angioedema (including tongue or lip swelling, periorbital edema, and face edema), and urticaria, have occurred in some patients during and after alglucosidase alfa infusions. Immune-mediated reactions presenting as proteinuria, nephrotic syndrome, and necrotizing skin lesions have occurred in some patients following alglucosidase alfa treatment. Closely observe patients during and after alglucosidase alfa administration and be prepared to manage anaphylaxis and hypersensitivity reactions. Inform patients of the signs and symptoms of anaphylaxis, hypersensitivity reactions, and immune-mediated reactions and have them seek immediate medical care should signs and symptoms occur.
Infantile-onset Pompe disease patients with compromised cardiac or respiratory function may be at risk of serious acute exacerbation of their cardiac or respiratory compromise due to fluid overload, and require additional monitoring.
WARNINGS AND PRECAUTIONS
Anaphylaxis and Hypersensitivity Reactions: Life-threatening anaphylaxis and hypersensitivity reactions have been observed in some patients during and after treatment with alglucosidase alfa. If anaphylaxis or severe hypersensitivity reactions occur, immediately discontinue infusion and institute appropriate medical treatment.
Immune-Mediated Reactions: Monitor patients for the development of systemic immune-mediated reactions involving skin and other organs.
Risk of Acute Cardiorespiratory Failure: Patients with compromised cardiac or respiratory function may be at risk of acute cardiorespiratory failure. Caution should be exercised when administering alglucosidase alfa to patients susceptible to fluid volume overload.
Risk of Cardiac Arrhythmia and Sudden Cardiac Death during General Anesthesia for Central Venous Catheter Placement: Caution should be used when administering general anesthesia for the placement of a central venous catheter intended for alglucosidase alfa infusion.
Appropriate medical support and monitoring measures should be available during infusion.
The most frequently reported adverse reactions (≥ 5%) in clinical trials were hypersensitivity reactions and included: anaphylaxis, rash, pyrexia, flushing/feeling hot, urticaria, headache, hyperhidrosis, nausea, cough, decreased oxygen saturation, tachycardia, tachypnea, chest discomfort, dizziness, muscle twitching, agitation, cyanosis, erythema, hypertension/increased blood pressure, pallor, rigors, tremor, vomiting, fatigue, and myalgia.
USE IN SPECIFIC POPULATIONS
Pregnancy: Based on animal data, alglucosidase alfa may cause fetal harm.
To report SUSPECTED ADVERSE REACTIONS, contact Genzyme at 1-800-745-4447 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch
Please see the full prescribing information for complete details, including boxed warning.
Reuser et al. Exp Cell Res. 1984;155(1):178-189.
Van der Ploeg et al. Pediatr Res. 1988 ;24(1):90-94.
Van der Ploeg et al. J Clin Invest. 1991;87(2):513-518.
Van der Ploeg et al, A randomized study of alglucosidase alfa in late-onset Pompe’s disease. N Engl J Med 2010, 362;15; 1396-1406.
Lumizyme Full Prescribing Information, Genzyme Corporation August 2014